-
1Academic Journal
المؤلفون: V. V. Naumova, E. K. Beltyukov, O. P. Kovtun, O. G. Smolenskaya, G. A. Bykova, E. S. Klyachina, В. В. Наумова, Е. К. Бельтюков, О. П. Ковтун, О. Г. Смоленская, Г. А. Быкова, Е. С. Клячина
المصدر: Meditsinskiy sovet = Medical Council; № 9 (2024); 47-61 ; Медицинский Совет; № 9 (2024); 47-61 ; 2658-5790 ; 2079-701X
مصطلحات موضوعية: неаллергическая эозинофилия, phenotypes of bronchial asthma, allergic asthma, eosinophilic asthma, non-allergic eosinophilia, фенотипы бронхиальной астмы, аллергическая астма, эозинофильная астма
وصف الملف: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8329/7349; Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. https://doi.org/10.1164/rccm.200906-0896oc.; Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–224. https://doi.org/10.1164/rccm.200711-1754OC.; Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2017;139(6):1797–1807. https://doi.org/10.1016/j.jaci.2016.08.048.; Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54–61. https://doi.org/10.1111/j.1440-1843.2006.00784.x.; Yan X, Chu JH, Gomez J, Koenigs M, Holm C, He X et al. Noninvasive analysis of the sputum transcriptome discriminates clinical phenotypes of asthma. Am J Respir Crit Care Med. 2015;191(10):1116–1125. https://doi.org/10.1164/rccm.201408-1440OC.; Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM et al. Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680–2688.e7. https://doi.org/10.1016/j.jaip.2021.02.059.; Rupani H, Murphy A, Bluer K, Renwick C, McQuitty P, Jackson DJ et al. Biologics in severe asthma: Which one, When and Where? Clin Exp Allergy. 2021;51(9):1225–1228. https://doi.org/10.1111/cea.13989.; Nagase H, Suzukawa M, Oishi K, Matsunaga K. Biologics for severe asthma: The real-world evidence, effectiveness of switching, and prediction factors for the efficacy. Allergol Int. 2023;72(1):11–23. https://doi.org/10.1016/j.alit.2022.11.008.; Ito A, Miyoshi S, Toyota H, Suzuki Y, Uehara Y, Hattori S et al. The overlapping eligibility for biologics in patients with severe asthma and phenotypes. Arerugi. 2022;71(3):210–220. (In Japan.) https://doi.org/10.15036/arerugi.71.210.; Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma. 2018;55(2):152–160. https://doi.org/10.1080/02770903.2017.1322611.; Астафьева НГ, Баранов АА, Вишнева ЕА, Дайхес НА, Жестков АВ, Ильина НИ и др. Аллергический ринит: клинические рекомендации. М.; 2020. 70 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/261_1.; Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl. 29):1–464. https://doi.org/10.4193/Rhin20.600.; Naumova V, Beltyukov E, Niespodziana K, Errhalt P, Valenta R, Karaulov A, Kiseleva D. Cumulative IgE-levels specific for respiratory allergens as biomarker to predict efficacy of anti-IgE-based treatment of severe asthma. Front Immunol. 2022;13:941492. https://doi.org/10.3389/fimmu.2022.941492.; Chen W, Sadatsafavi M, Tran TN, Murray RB, Wong CBN, Ali N et al. Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy. J Asthma Allergy. 2022;15:1491–1510. https://doi.org/10.2147/JAA.S377174.; Mansur AH, Gonem S, Brown T, Burhan H, Chaudhuri R, Dodd JW et al. Biologic therapy practices in severe asthma; outcomes from the UK Severe Asthma Registry and survey of specialist opinion. Clin Exp Allergy. 2023;53(2):173–185. https://doi.org/10.1111/cea.14222.; Korn S, Milger K, Skowasch D, Timmermann H, Taube C, Idzko M et al. The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control. Respir Med. 2022;195:106793. https://doi.org/10.1016/j.rmed.2022.106793.; Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021;160(3):814–830. https://doi.org/10.1016/j.chest.2021.04.013.; Baan EJ, de Roos EW, Engelkes M, de Ridder M, Pedersen L, Berencsi K et al. Characterization of Asthma by Age of Onset: A Multi-Database Cohort Study. J Allergy Clin Immunol Pract. 2022;10(7):1825–1834.e8. https://doi.org/10.1016/j.jaip.2022.03.019.; Quirce S, Heffler E, Nenasheva N, Demoly P, Menzies-Gow A, Moreira-Jorge A et al. Revisiting Late-Onset Asthma: Clinical Characteristics and Association with Allergy. J Asthma Allergy. 2020;13:743–752. https://doi.org/10.2147/JAA.S282205.; Principe S, Richards LB, Hashimoto S, Kroes JA, Van Bragt JJMH, Vijverberg SJ et al. Characteristics of severe asthma patients on biologics: a real-life European registry study. ERJ Open Res. 2023;9(3):00586-2022. https://doi.org/10.1183/23120541.00586-2022.; Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–360. https://doi.org/10.1016/j.jaci.2010.11.037.; Agache I, Akdis C, Jutel M, Virchow JC. Untangling asthma phenotypes and endotypes. Allergy. 2012;67(7):835–846. https://doi.org/10.1111/j.1398-9995.2012.02832.x.; Miljkovic D, Bassiouni A, Cooksley C, Ou J, Hauben E, Wormald PJ, Vreugde S. Association between group 2 innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis. Allergy. 2014;69(9):1154–1161. https://doi.org/10.1111/all.12440.; Наумова ВВ, Бельтюков ЕК, Киселева ДВ, Абдуллаев ВХ. Способ диагностики аллергической тяжелой бронхиальной астмы. Патент RU 2786010 C1, 24.12.2022. Режим доступа: https://new.fips.ru/registers-docview/fips_servlet?DB=RUPAT&DocNumber=2786010&TypeFile=html.; Jackson DJ, Busby J, Pfeffer PE, Menzies-Gow A, Brown T, Gore R et al. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. Thorax. 2021;76(3):220–227. https://doi.org/10.1136/thoraxjnl-2020-215168.; Lee JH, Kim HJ, Park CS, Park SY, Park SY, Lee H et al. Clinical Characteristics and Disease Burden of Severe Asthma According to Oral Corticosteroid Dependence: Real-World Assessment From the Korean Severe Asthma Registry (KoSAR). Allergy Asthma Immunol Res. 2022;14(4):412–423. https://doi.org/10.4168/aair.2022.14.4.412.; Tran TN, King E, Sarkar R, Nan C, Rubino A, O’Leary C et al. Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK. Eur Respir J. 2020;55(6):1902363. https://doi.org/10.1183/13993003.02363-2019.; Tran TN, MacLachlan S, Hicks W, Liu J, Chung Y, Zangrilli J et al. Oral Corticosteroid Treatment Patterns of Patients in the United States with Persistent Asthma. J Allergy Clin Immunol Pract. 2021;9(1):338–346.e3. https://doi.org/10.1016/j.jaip.2020.06.019.; Taube C, Bramlage P, Hofer A, Anderson D. Prevalence of oral corticosteroid use in the German severe asthma population. ERJ Open Res. 2019;5(4):00092-2019. https://doi.org/10.1183/23120541.00092-2019.; Graff S, Vanwynsberghe S, Brusselle G, Hanon S, Sohy C, Dupont LJ et al. Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian severe asthma registry. Respir Res. 2020;21(1):214. https://doi.org/10.1186/s12931-020-01460-7.; Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN et al. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2020;157(4):790–804. https://doi.org/10.1016/j.chest.2019.10.053.; Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1–12. https://doi.org/10.1016/j.jaci.2019.05.031.; Наумова ВВ, Бельтюков ЕК, Киселева ДВ, Быкова ГА, Смоленская ОГ, Штанова АА, Степина ДА. Таргетная терапия тяжёлой бронхиальной астмы: смена биологического препарата в реальной клинической практике – причины и следствие. Российский аллергологический журнал. 2024;20(4):439–454. https://doi.org/10.36691/RJA15993.; https://www.med-sovet.pro/jour/article/view/8329
-
2Academic Journal
المؤلفون: А. V. Budnevskiy, S. N. Аvdeev, S. А. Kozhevnikova, L. N. Аntakova, E. S. Ovsyannikov, V. V. Shishkina
المصدر: Туберкулез и болезни лёгких, Vol 100, Iss 1, Pp 61-66 (2022)
مصطلحات موضوعية: бронхиальная астма, фенотипы бронхиальной астмы, хроническое системное воспаление, мелатонин, Diseases of the respiratory system, RC705-779
وصف الملف: electronic resource
-
3Academic Journal
المؤلفون: S. K. Zyryanov, O. I. Butranova, С. К. Зырянов, О. И. Бутранова
المصدر: PULMONOLOGIYA; Том 28, № 5 (2018); 584-601 ; Пульмонология; Том 28, № 5 (2018); 584-601 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2018-28-5
مصطلحات موضوعية: февипипрант, phenotypes of bronchial asthma, genetically engineered drugs, humanized monoclonal antibodies, omalizumab, quilizumab, ligelizumab, lebrikizumab, tralokinumab, dupilumab, mepolizumab, benralizumab, fevipiprant, фенотипы бронхиальной астмы, генно-инженерно-биологические препараты, гуманизированное моноклональное антитело, омализумаб, квилизумаб, лигелизумаб, лебрикизумаб, тралокинумаб, дупилумаб, меполизумаб, бенрализумаб
وصف الملف: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/1058/867; Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur. Respir. Rev. 2012; 21 (123): 66–74. DOI:10.1183/09059180.00008111.; Desai M., Oppenheimer J. Elucidating asthma phenotypes and endotypes: progress towards personalized medicine. Ann. Allergy Asthma Immunol. 2016; 116 (5): 394–401. DOI:10.1016/j.anai.2015.12.024.; Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med. 2012; 18 (5): 716–725. DOI:10.1038/nm.2678.; Menzella F., Galeone C., Bertolini F. et al. Innovative treatments for severe refractory asthma: how to choose the right option for the right patient? J. Asthma Allergy. 2017; (10): 237–247. DOI:10.2147/JAA.S144100.; Oettgen H.C. Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J. Allergy Clin. Immunol. 2016; 137 (6): 1631–1645. DOI:10.1016/j.jaci.2016.04.009.; Bousquet J., Cabrera P., Berkman N. et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005; 60 (3): 302–308. DOI:10.1111/j.1398-9995.2004.00770.x.; Humbert M., Beasley R., Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60 (3): 309–316. DOI:10.1111/j.1398-9995.2004.00772.x.; Brusselle G., Michils A., Louis R. et al. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir. Med. 2009; 103 (11):1633–1642. DOI:10.1016/j.rmed.2009.06.014.; Braunstahl G.J., Chen C.W., Maykut R. et al. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Respir. Med. 2013; 107 (8) 1141–1151. DOI:10.1016/j.rmed.2013.04.017.; Milgrom H., Berger W., Nayak A. et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001; 108 (2): e36. DOI:10.1542/peds.108.2.e36.; Busse W.W., Morgan W.J., Gergen P.J. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 2011; 364 (11): 1005–1015. DOI:10.1056/NEJMoa1009705.; Brodlie M., McKean M.C., Moss S., Spencer D.A. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch. Dis. Child. 2012; 97 (7): 604–609. DOI:10.1136/archdischild-2011-301570.; Odajima H., Ebisawa M., Nagakura T. et al. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy. Allergol. Int. 2015; 64 (4): 364–370. DOI:10.1016/j.alit.2015.05.006.; Odajima H., Ebisawa M., Nagakura T. et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol. Int. 2017; 66 (1): 106–115. DOI:10.1016/j.alit.2016.06.004.; Deschildre A., Marguet C., Salleron J. et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur. Respir. J. 2013; 42 (5): 1224–1233. DOI:10.1183/09031936.00149812.; Deschildre A., Marguet C., Langlois C. et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur. Respir. J. 2015; 46 (3): 856–859. DOI:10.1183/09031936.00008115.; Campbell J.M., Wofford J.D., Knutsen A.P. Omalizumab treatment in children 6 to 18 years old with severe asthma at a children’s medical center. Pediatr. Allergy Immunol. Pulmonol. 2008; 21 (3): 123–148. DOI:10.1089/pai.2008.0502.; Corren J., Kavati A., Ortiz B. et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc. 2017; 38 (4): 250–263. DOI:10.2500/aap.2017.38.4067.; Lanier B., Bridges T., Kulus M. et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J. Allergy Clin. Immunol. 2009; 124 (6): 1210–1216. DOI:10.1016/j.jaci.2009.09.021.; Steiss J.O., Schmidt A., Nährlich L. et al. Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. Allergy Asthma Proc. 2012; 33 (1): 77–81. DOI:10.2500/aap.2012.33.3500.; Mansur A., Srivastava S., Mitchell V. et al. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety. Respir. Med. 2017; 124: 36–43. DOI:10.1016/j.rmed.2017.01.008.; Long A., Rahmaoui A., Rothman K.J. et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J. Allergy Clin. Immunol. 2014; 134 (3): 560–567. DOI:10.1016/j.jaci.2014.02.007.; Harris J.M., Maciuca R., Bradley M.S. et al. A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. Respir. Res. 2016; (17): 29. DOI:10.1186/s12931-016-0347-2.; Hanania N.A., Alpan O., Hamilos D.L. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med. 2011; 154 (9): 573–582. DOI:10.7326/0003-4819-154-9-201105030-00002.; Gauvreau G.M., Arm J.P., Boulet L.P. et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 2016; 138 (4): 1051-1059. DOI:10.1016/j.jaci.2016.02.027.; Hanania N.A., Noonan M., Corren J. et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015; 70 (8) 748–756. DOI:10.1136/thoraxjnl-2014-206719.; Scheerens H., Arron J.R., Zheng Y. et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin. Exp. Allergy. 2014; 44 (1): 38–46. DOI:10.1111/cea.12220.; Hanania N.A, Korenblat P., Chapman K.R. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 2016; 4 (10): 781–796. DOI:10.1016/S2213-2600(16)30265-X.; Panettieri R.A. Jr, Wang M., Braddock M. et al. Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. Immunotherapy. 2018; 10 (6): 473–490. DOI:10.2217/imt-2017-0191.; Simpson E.L., Flohr C., Eichenfield L.F. et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J. Am. Acad. Dermatol. 2018; 78 (5): 863–871. DOI:10.1016/j.jaad.2018.01.017.; Slager R.E., Otulana B.A., Hawkins G.A. et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist. J. Allergy Clin. Immunol. 2012; 130 (2): 516–522. DOI:10.1016/j.jaci.2012.03.030.; Shirley M. Dupilumab: First Global Approval. Drugs. 2017; 77 (10): 1115–1121. DOI:10.1007/s40265-017-0768-3.; Gooderham M.J., Hong H.C., Eshtiaghi P., Papp K.A. Dupilumab: a review of its use in the treatment of atopic dermatitis. J. Am. Acad. Dermatol. 2018; 78 (3, Suppl.1): S28–S36. DOI:10.1016/j.jaad.2017.12.022.; Pavord I.D., Korn S., Howarth P. et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651–659. DOI:10.1016/S0140-6736(12)60988-X.; Varricchi G., Senna G., Loffredo S. et al. Reslizumab and eosinophilic asthma: one step closer to precision medicine? Front Immunol. 2017; (8): 242. DOI:10.3389/fimmu.2017.00242.; Garcia G., Taille C., Laveneziana P. et al. Anti-interleukin-5 therapy in severe asthma. Eur. Respir. Rev. 2013; 22 (129): 251–257. DOI:10.1183/09059180.00004013.; Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2014; 371 (13): 1198–207. DOI:10.1056/NEJMoa1403290.; Varricchi G., Bagnasco D., Ferrando M. et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther. Adv. Respir. Dis. 2017; 11 (1): 40–45. DOI:10.1177/1753465816673303.; Menzies-Gow A., Flood-Page P., Sehmi R. et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol. 2003; 111 (4): 714–719. DOI:10.1067/mai.2003.1382.; Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 2003; 167 (2): 199–204. DOI:10.1164/rccm.200208-789OC.; Flood-Page P., Swenson C., Faiferman I. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 2007; 176 (11): 1062–1071. DOI:10.1164/rccm.200701-085OC.; Haldar P., Brightling C. E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009; 360 (10): 973–984. DOI:10.1056/NEJMoa0808991.; Nair P., Pizzichini M.M., Kjarsgaard M. et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 2009; 360 (10): 985–993. DOI:10.1056/NEJMoa0805435.; Bel E.H., Wenzel S.E., Thompson P.J. et al. SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med. 2014; 371 (13): 1189–1197. DOI:10.1056/NEJMoa1403291.; Haldar P., Brightling C.E., Singapuri A. et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J. Allergy Clin. Immunol. 2014; 133 (3): 921–923. DOI:10.1016/j.jaci.2013.11.026.; Lugogo N., Domingo C., Chanez P. et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin. Ther. 2016; 38 (9): 2058–2070. DOI:10.1016/j.clinthera.2016.07.010.; Chupp G.L., Bradford E.S., Albers F.C. et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir. Med. 2017; 5 (5): 390–400. DOI:10.1016/S2213-2600(17)30125-X.; Yancey S.W., Ortega H.G., Keene O.N. et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J. Allergy Clin. Immunol. 2017; 139 (4): 1167–1175. DOI:10.1016/j.jaci.2016.08.008.; Castro M., Mathur S., Hargreave F. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 2011; 184 (10): 1125–1132. DOI:10.1164/rccm.201103-0396OC.; Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 2015; 3 (5): 355–366. DOI:10.1016/S2213-2600(15)00042-9.; Bjermer L., Lemiere C., Maspero J. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016; 150 (4): 789–798. DOI:10.1016/j.chest.2016.03.032.; Corren J., Weinstein S., Janka L. et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016; 150 (4): 799–810. DOI:10.1016/j.chest.2016.03.018.; Pelaia C., Vatrella A., Bruni A. et al. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des. Devel. Ther. 2018; 12: 619–628. DOI:10.2147/DDDT.S155307.; Busse W.W., Katial R., Gossage D. et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 2010; 125 (6):1237–1244 e2. DOI:10.1016/j.jaci.2010.04.005.; Laviolette M., Gossage D.L., Gauvreau G. et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J. Allergy Clin. Immunol. 2013; 132 (5): 1086–1096 e5. DOI:10.1016/j.jaci.2013.05.020.; Park H.S., Kim M.K., Imai N. et al. A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int. Arch. Allergy Immunol. 2016; 169 (3): 135–145. DOI:10.1159/000444799.; Castro M., Wenzel S.E., Bleecker E.R. et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir. Med. 2014; 2 (11): 879–890. DOI:10.1016/S2213-2600(14)70201-2.; Nowak R.M., Parker J.M., Silverman R.A. et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am. J. Emerg. Med. 2015; 33 (1): 14–20. DOI:10.1016/j.ajem.2014.09.036.; Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2115–2127. DOI:10.1016/S0140-6736(16)31324-1.; FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388 (10056): 2128–2141. DOI:10.1016/S0140-6736(16)31322-8.; Nair P., Wenzel S., Rabe K.F. et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N. Engl. J. Med. 2017; 376 (25): 2448–2458. DOI:10.1056/NEJMoa1703501.; Ferguson G.T., FitzGerald J.M., Bleecker E.R. et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2017; 5 (7): 568–576. DOI:10.1016/S2213-2600(17)30190-X.; Matera M.G., Calzetta L., Rinaldi B., Cazzola M. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opin. Drug Metab. Toxicol. 2017; 13 (9): 1007–1013. DOI:10.1080/17425255.2017.1359253.; Liu T., Wang F., Wang G. et al. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. Front Med. 2018; 12 (3): 340–349. DOI:10.1007/s11684-017-0565-0.; FitzGerald J.M., Bleecker E.R., Menzies-Gow A. et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir. Med. 2018; 6 (1): 51–64. DOI:10.1016/S2213-2600(17)30344-2.; Chipps B.E., Newbold P., Hirsch I. et al. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann. Allergy Asthma Immunol. 2018; 120 (5): 504–511. DOI:10.1016/j.anai.2018.01.030.; Albers F.C., Müllerová H., Gunsoy N.B. et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J. Asthma. 2017; 55 (2): 152–160. DOI:10.1080/02770903.2017.1322611.; Albers F.C., Liu M.C., Chipps B.E. et al. Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): asthma control, quality of life and lung function outcomes. J. Allergy Clin. Immunol. 2018; 141 (2): AB408. DOI:10.1016/j.jaci.2017.12.964.; Erpenbeck V.J., Popov T.A., Miller D. et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm. Pharmacol. Ther. 2016; (39): 54–63. DOI:10.1016/j.pupt.2016.06.005.; Gonem S., Berair R., Singapuri A. et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: single-centre, randomised, double-blind, parallel-group, placebo controlled trial. Lancet Respir. Med. 2016; 4 (9): 699–707. DOI:10.1016/S2213-2600(16)30179-5.; Bateman E.D., Guerreros A.G., Brockhaus F. et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur. Respir. J. 2017: 50 (2): pii: 1700670. DOI:10.1183/13993003.00670-2017.; https://journal.pulmonology.ru/pulm/article/view/1058
-
4Academic Journal
المؤلفون: Ненашева, Наталья
مصطلحات موضوعية: БРОНХИАЛЬНАЯ АСТМА,ФЕНОТИПЫ БРОНХИАЛЬНОЙ АСТМЫ,ЭНДОТИПЫ БРОНХИАЛЬНОЙ АСТМЫ,ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ
وصف الملف: text/html
-
5Academic Journal
المؤلفون: Наталья, Михайловна
مصطلحات موضوعية: бронхиальная астма, фенотипы бронхиальной астмы, эндотипы бронхиальной астмы, ингаляционные глюкокортикостероиды
وصف الملف: text/html
-
6Academic Journal
المؤلفون: Авдеев, Сергей, Айсанов, Заурбек, Архипов, Владимир, Белевский, Андрей, Геппе, Наталья, Илькович, Михаил, Княжеская, Надежда, Ненашева, Наталья, Овчаренко, Светлана, Степанян, Игорь, Фассахов, Рустэм, ШМЕЛЕВ
وصف الملف: text/html
-
7Academic Journal
المؤلفون: Давидовская, Е. И., Барановская, Т. В., Рузанов, Д. Ю.
مصطلحات موضوعية: бронхиальная астма, фенотипы бронхиальной астмы, биологические препараты, таргетные препараты, персонифицированная терапия, моноклональные антитела, глюкокортикостероиды, согласительный доклад экспертов
Relation: Давидовская, Е. И. Перспективы персонализированной терапии тяжелой бронхиальной астмы / Е. И. Давидовская, Т. В. Барановская, Д. Ю. Рузанов // Рецепт. - 2019. - Т. 22, № 2. - С. 276-286.; http://elib.gsmu.by/handle/GomSMU/5115
-
8
المصدر: Практическая пульмонология.
مصطلحات موضوعية: БРОНХИАЛЬНАЯ АСТМА,ФЕНОТИПЫ БРОНХИАЛЬНОЙ АСТМЫ,ЭНДОТИПЫ БРОНХИАЛЬНОЙ АСТМЫ,ИНГАЛЯЦИОННЫЕ ГЛЮКОКОРТИКОСТЕРОИДЫ
وصف الملف: text/html
-
9
المصدر: Практическая пульмонология.
وصف الملف: text/html
-
10Academic Journal
المؤلفون: Zyryanov S.K., Butranova O.I.
المصدر: Pulmonologiya
مصطلحات موضوعية: Benralizumab, Bronchial asthma, Dupilumab, Fevipiprant, Genetically engineered drugs, Humanized monoclonal antibodies, Lebrikizumab, Ligelizumab, Mepolizumab, Omalizumab, Phenotypes of bronchial asthma, Quilizumab, Tralokinumab, бронхиальная астма, фенотипы бронхиальной астмы, генно-инженерно-биологические препараты, гуманизированное моноклональное антитело, омализумаб, квилизумаб, лигелизумаб, лебрикизумаб, тралокинумаб, дупилумаб, меполизумаб, бенрализумаб, февипипрант
-
11Dissertation/ Thesis
-
12Dissertation/ Thesis
